Publication

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens, W. J., Lund, V., Bachert, C., Mullol, J., Bjermer, L., Bousquet, J., Canonica, G. W., Deneyer, L., Desrosiers, M., Diamant, Z., Han, J., Heffler, E., Hopkins, C., Jankowski, R., Joos, G., Knill, A., Lee, J., Lee, S. E., Marien, G., Pugin, B., Senior, B., Seys, S. F. & Hellings, P. W., 15-Jul-2019, In : Allergy. 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Fokkens, W. J., Lund, V., Bachert, C., Mullol, J., Bjermer, L., Bousquet, J., ... Hellings, P. W. (2019). EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. https://doi.org/10.1111/all.13875

Author

Fokkens, Wytske J. ; Lund, Valerie ; Bachert, Claus ; Mullol, Joaquim ; Bjermer, Leif ; Bousquet, Jean ; Canonica, Giorgio W. ; Deneyer, Lauren ; Desrosiers, Martin ; Diamant, Zuzana ; Han, Joseph ; Heffler, Enrico ; Hopkins, Claire ; Jankowski, Roger ; Joos, Guy ; Knill, Andrew ; Lee, Jivianne ; Lee, Stella E. ; Marien, Gert ; Pugin, Benoit ; Senior, Brent ; Seys, Sven F. ; Hellings, Peter W. / EUFOREA consensus on biologics for CRSwNP with or without asthma. In: Allergy. 2019.

Harvard

Fokkens, WJ, Lund, V, Bachert, C, Mullol, J, Bjermer, L, Bousquet, J, Canonica, GW, Deneyer, L, Desrosiers, M, Diamant, Z, Han, J, Heffler, E, Hopkins, C, Jankowski, R, Joos, G, Knill, A, Lee, J, Lee, SE, Marien, G, Pugin, B, Senior, B, Seys, SF & Hellings, PW 2019, 'EUFOREA consensus on biologics for CRSwNP with or without asthma', Allergy. https://doi.org/10.1111/all.13875

Standard

EUFOREA consensus on biologics for CRSwNP with or without asthma. / Fokkens, Wytske J.; Lund, Valerie; Bachert, Claus; Mullol, Joaquim; Bjermer, Leif; Bousquet, Jean; Canonica, Giorgio W.; Deneyer, Lauren; Desrosiers, Martin; Diamant, Zuzana; Han, Joseph; Heffler, Enrico; Hopkins, Claire; Jankowski, Roger; Joos, Guy; Knill, Andrew; Lee, Jivianne; Lee, Stella E.; Marien, Gert; Pugin, Benoit; Senior, Brent; Seys, Sven F.; Hellings, Peter W.

In: Allergy, 15.07.2019.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019 Jul 15. https://doi.org/10.1111/all.13875


BibTeX

@article{c318eacf412f41f099c0396571e95662,
title = "EUFOREA consensus on biologics for CRSwNP with or without asthma",
abstract = "Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.",
keywords = "asthma, biologics, chronic rhinosinusitis, nasal polyps, type 2 inflammation, ENDOSCOPIC SINUS SURGERY, ADULT CHRONIC RHINOSINUSITIS, NATIONAL COMPARATIVE AUDIT, QUALITY-OF-LIFE, NASAL POLYPOSIS, OMALIZUMAB, PREVALENCE, MANAGEMENT, ALLERGY, CORTICOSTEROIDS",
author = "Fokkens, {Wytske J.} and Valerie Lund and Claus Bachert and Joaquim Mullol and Leif Bjermer and Jean Bousquet and Canonica, {Giorgio W.} and Lauren Deneyer and Martin Desrosiers and Zuzana Diamant and Joseph Han and Enrico Heffler and Claire Hopkins and Roger Jankowski and Guy Joos and Andrew Knill and Jivianne Lee and Lee, {Stella E.} and Gert Marien and Benoit Pugin and Brent Senior and Seys, {Sven F.} and Hellings, {Peter W.}",
year = "2019",
month = "7",
day = "15",
doi = "10.1111/all.13875",
language = "English",
journal = "Allergy",
issn = "0105-4538",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - EUFOREA consensus on biologics for CRSwNP with or without asthma

AU - Fokkens, Wytske J.

AU - Lund, Valerie

AU - Bachert, Claus

AU - Mullol, Joaquim

AU - Bjermer, Leif

AU - Bousquet, Jean

AU - Canonica, Giorgio W.

AU - Deneyer, Lauren

AU - Desrosiers, Martin

AU - Diamant, Zuzana

AU - Han, Joseph

AU - Heffler, Enrico

AU - Hopkins, Claire

AU - Jankowski, Roger

AU - Joos, Guy

AU - Knill, Andrew

AU - Lee, Jivianne

AU - Lee, Stella E.

AU - Marien, Gert

AU - Pugin, Benoit

AU - Senior, Brent

AU - Seys, Sven F.

AU - Hellings, Peter W.

PY - 2019/7/15

Y1 - 2019/7/15

N2 - Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

AB - Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

KW - asthma

KW - biologics

KW - chronic rhinosinusitis

KW - nasal polyps

KW - type 2 inflammation

KW - ENDOSCOPIC SINUS SURGERY

KW - ADULT CHRONIC RHINOSINUSITIS

KW - NATIONAL COMPARATIVE AUDIT

KW - QUALITY-OF-LIFE

KW - NASAL POLYPOSIS

KW - OMALIZUMAB

KW - PREVALENCE

KW - MANAGEMENT

KW - ALLERGY

KW - CORTICOSTEROIDS

U2 - 10.1111/all.13875

DO - 10.1111/all.13875

M3 - Review article

JO - Allergy

JF - Allergy

SN - 0105-4538

ER -

ID: 96178118